enGene Therapeutics Inc (ENGN) vs PolyPid Ltd. (PYPD)

enGene Therapeutics Inc and PolyPid Ltd. are both Biotechnology companies. enGene Therapeutics Inc and PolyPid Ltd. are of similar size ($115.2M and $112.6M). Across the 9 metrics below, PolyPid Ltd. leads on 5 and enGene Therapeutics Inc on 4.

Valuation

Metric ENGN PYPD Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 0.53 25.59 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.86 n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (117.61%) (24.30%) (32.88%)
Free cash flow yield (84.73%) (55.78%) (23.13%)

Profitability

Metric ENGN PYPD Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (60.50%) (243.59%) (51.96%)
Return on assets (48.84%) (119.05%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENGN PYPD Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (56.85%) 57.43% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENGN PYPD Biotechnology median
Debt to equity 0.11 0.00 0.00
Current ratio 10.21 1.35 4.97
Net debt to EBITDA 1.42 0.39 1.01

Dividend

Metric ENGN PYPD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENGN PYPD Biotechnology median
Market cap 112.59m 115.16m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack